{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:18Z","timestamp":1787020158410,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2245-8","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T09:25:42Z","timestamp":1487064342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9\u00a0months of isoniazid, 4\u00a0months of rifampin and 3\u00a0months of isoniazid and rifapentine"],"prefix":"10.1186","volume":"17","author":[{"given":"Adelaide H.","family":"McClintock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKenna","family":"Eastment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy M.","family":"McKinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline L.","family":"Pitney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shireesha","family":"Dhanireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,14]]},"reference":[{"key":"2245_CR1","unstructured":"Millennium Development Goals (MDGs). May 2015. At http:\/\/www.who.int\/mediacentre\/factsheets\/fs290\/en\/ . Accessed 6 June 2015."},{"key":"2245_CR2","unstructured":"Tuberculosis, Data and Statistics. April 23, 2014. (Accessed 6 June 2015, 2015, at http:\/\/www.cdc.gov\/tb\/statistics\/default.htm .)"},{"key":"2245_CR3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140881","volume":"10","author":"R Miramontes","year":"2015","unstructured":"Miramontes R, Hill AN, Yelk Woodruff RS, et al. Tuberculosis Infection in the United States: Prevalence Estimates from the National Health and Nutrition Examination Survey, 2011-2012. PLoS One. 2015;10, e0140881.","journal-title":"PLoS One"},{"key":"2245_CR4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1164\/rccm.200701-057OC","volume":"177","author":"DE Bennett","year":"2008","unstructured":"Bennett DE, Courval JM, Onorato I, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med. 2008;177:348\u201355.","journal-title":"Am J Respir Crit Care Med"},{"key":"2245_CR5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1471-2458-6-157","volume":"6","author":"TC Porco","year":"2006","unstructured":"Porco TC, Lewis B, Marseille E, Grinsdale J, Flood JM, Royce SE. Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants. BMC Public Health. 2006;6:157.","journal-title":"BMC Public Health"},{"key":"2245_CR6","first-page":"265","volume":"64","author":"D Colleen Scott","year":"2014","unstructured":"Colleen Scott D, Hannah L, Kirking M, Carla Jeffries J, Price SF, Pratt R. Tuberculosis Trends - United States, 2014. Morbidity and Mortality Weekly Report (MMWR). 2014;64:265\u2013369.","journal-title":"Morbidity and Mortality Weekly Report (MMWR)"},{"key":"2245_CR7","unstructured":"Centers for Disease C. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2000;49:2."},{"key":"2245_CR8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M14-1019","volume":"161","author":"HR Stagg","year":"2014","unstructured":"Stagg HR, Zenner D, Harris RJ, Munoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161:419\u201328.","journal-title":"Ann Intern Med"},{"key":"2245_CR9","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/1471-2458-12-468","volume":"12","author":"ND Goswami","year":"2012","unstructured":"Goswami ND, Gadkowski LB, Piedrahita C, et al. Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health. 2012;12:468.","journal-title":"BMC Public Health"},{"key":"2245_CR10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3200\/JACH.57.5.553-556","volume":"57","author":"K Hess","year":"2009","unstructured":"Hess K, Goad J, Wu J, Johnson K. Isoniazid completion rates for latent tuberculosis infection among college students managed by a community pharmacist. J Am Coll Health. 2009;57:553\u20135.","journal-title":"J Am Coll Health"},{"key":"2245_CR11","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.17269\/cjph.104.3643","volume":"104","author":"P Rivest","year":"2013","unstructured":"Rivest P, Street MC, Allard R. Completion rates of treatment for latent tuberculosis infection in Quebec, Canada from 2006 to 2010. Can J Public Health. 2013;104:e235\u20139.","journal-title":"Can J Public Health"},{"key":"2245_CR12","unstructured":"Centers for Disease C. Recommendations for Use of an Isoniazid\u2013Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection. MMWR Morb Mortal Wkly Rep 2011;60:1650-3."},{"key":"2245_CR13","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(02)09742-8","volume":"360","author":"D Benator","year":"2002","unstructured":"Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002;360:528\u201334.","journal-title":"Lancet"},{"key":"2245_CR14","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.200512-1953OC","volume":"173","author":"M Schechter","year":"2006","unstructured":"Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine\/isoniazid or daily rifampin\/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med. 2006;173:922\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"2245_CR15","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155\u201366.","journal-title":"N Engl J Med"},{"key":"2245_CR16","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","volume":"46","author":"H Getahun","year":"2015","unstructured":"Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46:1563\u201376.","journal-title":"Eur Respir J"},{"key":"2245_CR17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.5588\/ijtld.13.0423","volume":"17","author":"D Shepardson","year":"2013","unstructured":"Shepardson D, Marks SM, Chesson H, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis. 2013;17:1531\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2245_CR18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5588\/ijtld.14.0052","volume":"18","author":"D Shepardson","year":"2014","unstructured":"Shepardson D, MacKenzie WR. Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices. Int J Tuberc Lung Dis. 2014;18:751.","journal-title":"Int J Tuberc Lung Dis"},{"key":"2245_CR19","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","volume":"179","author":"DP Holland","year":"2009","unstructured":"Holland DP, Sanders GD, Hamilton CD, Stout JE. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med. 2009;179:1055\u201360.","journal-title":"Am J Respir Crit Care Med"},{"key":"2245_CR20","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1378\/chest.130.6.1712","volume":"130","author":"A Lardizabal","year":"2006","unstructured":"Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4\u00a0months of rifampin. Chest. 2006;130:1712\u20137.","journal-title":"Chest"},{"key":"2245_CR21","first-page":"w13240","volume":"141","author":"I Fresard","year":"2011","unstructured":"Fresard I, Bridevaux PO, Rochat T, Janssens JP. Adverse effects and adherence to treatment of rifampicin 4\u00a0months vs isoniazid 6\u00a0months for latent tuberculosis: a retrospective analysis. Swiss Med Wkly. 2011;141:w13240.","journal-title":"Swiss Med Wkly"},{"key":"2245_CR22","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","volume":"372","author":"H Getahun","year":"2015","unstructured":"Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372:2127\u201335.","journal-title":"N Engl J Med"},{"key":"2245_CR23","volume-title":"Stata","author":"StataCorp","year":"2013","unstructured":"StataCorp. Stata. 13th ed. College Station, TX: Stata Corp L; 2013.","edition":"13"},{"key":"2245_CR24","doi-asserted-by":"crossref","unstructured":"Center for Disease Control. TB Notes Newsletter No. 3. 2012. Accessed 5 Nov 5 2012.","DOI":"10.5962\/p.381258"},{"key":"2245_CR25","first-page":"257","volume":"133","author":"D Menzies","year":"2011","unstructured":"Menzies D, Al Jahdali H, Al OB. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res. 2011;133:257\u201366.","journal-title":"Indian J Med Res"},{"key":"2245_CR26","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","volume":"149","author":"D Menzies","year":"2008","unstructured":"Menzies D, Long R, Trajman A, et al. Adverse events with 4\u00a0months of rifampin therapy or 9\u00a0months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149:689\u201397.","journal-title":"Ann Intern Med"},{"key":"2245_CR27","first-page":"CD007952","volume":"9","author":"EE Lutge","year":"2015","unstructured":"Lutge EE, Wiysonge CS, Knight SE, Sinclair D, Volmink J. Incentives and enablers to improve adherence in tuberculosis. Cochrane Database Syst Rev. 2015;9:CD007952.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2245-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T09:23:20Z","timestamp":1719048200000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2245-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,14]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2245"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2245-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,14]]},"article-number":"146"}}